AstraZeneca (NASDAQ: AZN), recognized as the world's sixth-largest pharmaceutical entity by market capitalization, made a bold proclamation in May 2014. The company set an ambitious goal of achieving annual revenue exceeding $45 billion by 2023.

This target was met with skepticism by Wall Street and dismissed as excessively optimistic. Contrary to these doubts, however, AstraZeneca realized this revenue milestone and surpassed the S&P 500 in total returns, including dividends, within the same time frame.

Continue reading

Source Fool.com